The Lancet January 09, 2021

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti, et al.

Bottom Line

A pooled interim analysis of randomized controlled trials demonstrated that the ChAdOx1 nCoV-19 vaccine is safe and provides an overall efficacy of 70.4% against symptomatic COVID-19, completely preventing severe disease and hospitalization.

Key Findings

1. Overall vaccine efficacy against symptomatic COVID-19 more than 14 days after the second dose was 70.4% (95.8% CI, 54.8 to 80.6) [2.2.1].

2. Efficacy varied notably by the dosing regimen administered: it was 62.1% (95% CI, 41.0 to 75.7) in the cohort of 8,895 participants receiving two standard doses (SD/SD).

3. In a smaller cohort of 2,741 participants who inadvertently received a low dose followed by a standard dose (LD/SD), efficacy was substantially higher at 90.0% (95% CI, 67.4 to 97.0).

4. Starting 21 days after the first dose, 10 participants were hospitalized for COVID-19, all of whom were in the control arm; two of these cases were severe, including one death.

5. The vaccine demonstrated an acceptable safety profile across the 23,848 overall enrolled participants, with no severe adverse events directly attributed to the vaccine in the interim analysis.

Study Design

Design

Pooled Analysis of RCTs

Single-Blind

Sample

11,636

Patients

Duration

Interim (Nov 4, 2020 cutoff)

Median

Setting

UK, Brazil, South Africa

Population Adults aged ≥18 years (predominantly 18-55 years in the efficacy cohort)

Intervention Two doses of ChAdOx1 nCoV-19 vaccine (either standard/standard or low/standard dose)

Comparator Meningococcal conjugate vaccine (MenACWY) or saline placebo

Outcome Virologically confirmed, symptomatic COVID-19 ≥14 days after the second dose

Study Limitations

• Heterogeneity in trial protocols, distinct dosing regimens, and variable prime-boost intervals across the UK, Brazil, and South Africa cohorts complicated the pooled efficacy interpretation [2.2.1].

• The highly efficacious LD/SD regimen was not a prespecified design but arose from a dosing miscalculation in the UK trial.

• The primary efficacy cohort predominantly comprised younger adults aged 18-55 years, limiting the certainty regarding efficacy in older, higher-risk populations at the time of the interim analysis.

• The interim nature of the analysis inherently meant short follow-up time, restricting the ability to assess long-term efficacy or waning immunity.

Clinical Significance

This trial definitively established the clinical viability of a viral-vector vaccine against SARS-CoV-2, proving it highly effective in preventing symptomatic illness and completely protective against severe COVID-19 hospitalization and death. Its relative low cost and compatibility with standard refrigerator temperatures (2-8°C) made it uniquely suited for rapid global distribution, particularly in resource-limited settings.

Historical Context

Published simultaneously with the early pivotal data for the mRNA COVID-19 vaccines in late 2020, this analysis represented a watershed moment in the pandemic response. The Oxford-AstraZeneca (ChAdOx1) vaccine became the backbone of the COVAX initiative, distributing billions of doses globally. Later clinical updates and pharmacovigilance would identify the rare risk of vaccine-induced immune thrombotic thrombocytopenia (VITT) and reduced efficacy against certain emerging variants, which subsequently shifted vaccination strategies in some high-income nations.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the mechanism of action of the ChAdOx1 nCoV-19 vaccine, and why is a chimpanzee adenovirus vector used instead of a human adenovirus vector?

Key Response

ChAdOx1 uses a replication-deficient chimpanzee adenovirus to deliver the SARS-CoV-2 spike protein gene to host cells. A chimpanzee vector is specifically utilized to circumvent pre-existing immunity to common human adenoviruses, which could prematurely neutralize the viral vector before it delivers the genetic payload, thereby reducing overall vaccine efficacy.

Resident

In the context of the ChAdOx1 vaccine trials reporting complete protection against severe disease but approximately 70 percent overall efficacy against symptomatic infection, how should you counsel a patient hesitant to receive the vaccine due to fears of breakthrough mild illness?

Key Response

Residents must translate trial endpoints into effective patient counseling. The primary clinical and public health goal of vaccination is mitigating severe outcomes like hospitalization, intubation, and death, which this vaccine completely prevented in the trial cohort. While breakthrough mild infections can still occur, counseling should emphasize that the prevention of life-threatening disease is the paramount benefit.

Fellow

The interim analysis revealed a paradoxical finding where the low-dose/standard-dose regimen had higher efficacy compared to the standard-dose/standard-dose regimen. What immunological phenomena might explain this dose-dependent discrepancy?

Key Response

This addresses a famous quirk of the AstraZeneca trial. Fellows should understand potential mechanisms like anti-vector immunity. An initial high dose may generate strong immunity against the adenovirus vector itself, blunting the immune response to the booster dose. A lower initial dose might sufficiently prime the spike protein response while minimizing neutralizing antibodies against the viral vector.

Attending

Evaluating pooled data from the UK, Brazil, and South Africa with varying circulating variants at the time of the trial, how does the geographical heterogeneity of the study populations inform your clinical perspective on the vaccine utility?

Key Response

Attendings must weigh how real-world variables like emerging variants impact pooled efficacy data. Geographic diversity strengthens the overall applicability of the findings but requires careful subgroup analysis to ensure efficacy holds up against localized dominant strains, emphasizing the ongoing need for genomic surveillance when adopting global trial data into local practice.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The researchers conducted a pooled analysis of four distinct RCTs utilizing different control groups and dosing intervals. What are the major methodological limitations of pooling data from trials with heterogeneous protocols to calculate a combined efficacy estimate?

Key Response

Pooling disparate trials introduces significant confounding. Combining data with different protocols, varying delays between doses, and different control arms (MenACWY vs. saline) violates the strict randomization integrity of individual trials if not pre-specified rigorously. This complicates the interpretation of a single point estimate for efficacy and introduces confounding risks.

Journal Editor

As a peer reviewer assessing this interim analysis, how do you evaluate the investigators decision to include the accidentally administered low-dose/standard-dose cohort in the primary efficacy analysis, and what are the editorial implications of publishing findings heavily influenced by a protocol deviation?

Key Response

Journal editors focus on methodological integrity. The low-dose/standard-dose group resulted from a dosing error rather than a planned study arm. Including it in a pooled primary efficacy calculation artificially inflates the overall result and raises questions about post-hoc data dredging. A rigorous editorial review would demand strict sensitivity analyses excluding the error group to maintain validity.

Guideline Committee

Given the interim finding of 70.4 percent efficacy against symptomatic disease but 100 percent protection against severe disease, how should vaccine guideline committees prioritize the rollout of ChAdOx1 in resource-limited settings compared to higher-efficacy mRNA vaccines?

Key Response

Guideline committees must balance efficacy, safety, and logistical feasibility. While mRNA vaccines showed greater than 90 percent efficacy, the standard refrigeration requirements of ChAdOx1 and its complete protection against severe disease made it a strong recommendation for global rollout (e.g., WHO SAGE guidelines). Committees must prioritize preventing healthcare system collapse over sterilizing immunity when logistical constraints are high.

Clinical Landscape

Noteworthy Related Trials

2020

BNT162b2 Phase 3 Trial

n = 43,548 · NEJM

Tested

BNT162b2 (mRNA COVID-19 vaccine) 30 μg, two doses

Population

Healthy adults or those with stable chronic medical conditions

Comparator

Placebo

Endpoint

Efficacy against confirmed COVID-19 with onset at least 7 days after the second dose

Key result: The vaccine showed 95% efficacy in preventing COVID-19 and had a similar safety profile to other viral vaccines.

2020

COVE Trial

n = 30,420 · NEJM

Tested

mRNA-1273 (Moderna COVID-19 vaccine) 100 μg, two doses

Population

Adults at high risk for SARS-CoV-2 infection or its complications

Comparator

Placebo

Endpoint

Prevention of symptomatic COVID-19 illness at least 14 days after the second dose

Key result: The mRNA-1273 vaccine demonstrated 94.1% efficacy at preventing COVID-19 illness, including severe disease.

2021

ENSEMBLE Trial

n = 43,783 · NEJM

Tested

Ad26.COV2.S (Janssen COVID-19 vaccine) single dose

Population

Adults aged 18 years and older

Comparator

Placebo

Endpoint

Efficacy against moderate to severe-critical COVID-19 at 14 and 28 days post-vaccination

Key result: A single dose of Ad26.COV2.S protected against symptomatic COVID-19 with 66.9% efficacy and was highly effective against severe disease.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis